Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, INTERVENTIONAL, MULTICENTER, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-PAOD FOR THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAOD)

Next Previous
Trial Profile

A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, INTERVENTIONAL, MULTICENTER, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-PAOD FOR THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAOD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs APZ 2 (Primary)
  • Indications Peripheral arterial occlusive disorders
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors RHEACELL

    • Most Recent Events

    • 22 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 31 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top